

TEKLA HEALTHCARE INVESTORS
Form N-Q
August 26, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0578
Expires: March 31, 2019
Estimated average burden
hours per response.....10.5

FORM N-Q

**QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number 811-04889

Tekla Healthcare Investors
(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA
(Address of principal executive offices)

02110
(Zip code)

(Name and address of agent for service)

Registrant's telephone number, including area code: 617-772-8500

Date of fiscal year end: September 30

Date of reporting period: 6/30/16

Item 1. Schedule of Investments.

TEKLA HEALTHCARE INVESTORS**SCHEDULE OF INVESTMENTS**

JUNE 30, 2016

(Unaudited)

SHARES		VALUE
	CONVERTIBLE PREFERRED AND WARRANTS (Restricted) (a) (b) 4.9% of Net Assets	
	Biotechnology 1.2%	
1,426,649	Afferent Pharmaceuticals, Inc. Series C	\$ 6,890,728
1,553,255	BioClin Therapeutics, Inc. Series A	1,009,616
3,696,765	EBI Life Sciences, Inc. Series A (c)	18,854
2,266,666	GenomeDx Biosciences, Inc. Series C	3,399,999
		11,319,197
	Health Care Equipment & Supplies 2.2%	
3,364,723	AlterG, Inc. Series C	1,379,536
114,158	CardioKinetix, Inc. Series C	114
205,167	CardioKinetix, Inc. Series D	522,765
632,211	CardioKinetix, Inc. Series E	1,799,905
580,225	CardioKinetix, Inc. Series F	1,982,049
	N/A(e) CardioKinetix, Inc. warrants (expiration 12/11/19)	0
	N/A(e) CardioKinetix, Inc. warrants (expiration 6/03/20)	0
12,695	CardioKinetix, Inc. warrants (expiration 8/15/24)	0
951,000	IlluminOss Medical, Inc. Series AA (c)	951,000
895,848	IlluminOss Medical, Inc. Series Junior Preferred (c)	895,848
11,410,347	Insightra Medical, Inc. Series C (c)	11,410
8,661,370	Insightra Medical, Inc. Series C-2 (c)	8,661
815,025	Insightra Medical, Inc. warrants (expiration 3/31/25) (c)	0
4,482,636	Insightra Medical, Inc. warrants (expiration 5/28/25) (c)	0
3,260,100	Insightra Medical, Inc. warrants (expiration 8/18/25) (c)	0
13,823,805	Palyon Medical Corporation Series A (c)	2,944
27,100,879	Palyon Medical Corporation Series B (c)	1,897
	N/A(e) Palyon Medical Corporation warrants (expiration 4/26/19) (c)	0
4,720,000	Tibion Corporation Series B	0
	N/A(e) Tibion Corporation warrants (expiration 07/12/17)	0
	N/A(e) Tibion Corporation warrants (expiration 10/30/17)	0
	N/A(e) Tibion Corporation warrants (expiration 11/28/17)	0
3,750,143	Veniti, Inc. Series A (c)	6,880,013
1,881,048	Veniti, Inc. Series B (c)	3,545,023
1,031,378	Veniti, Inc. Series C (c)	2,179,714
		20,160,879
	Life Sciences Tools & Services 0.7%	
3,109,861	Dynex Technologies, Inc. Series A	1,554,931
142,210	Dynex Technologies, Inc. warrants (expiration 4/01/19)	0
11,335	Dynex Technologies, Inc. warrants (expiration 5/06/19)	0
3,669,024	Labcyte, Inc. Series C	4,274,413
160,767	Labcyte, Inc. Series D	168,484
		5,997,828
	Pharmaceuticals 0.8%	
4,118,954	Euthymics Biosciences, Inc. Series A (c)	4,119
77,632	Neurovance, Inc. Series A (c)	288,015
965,354	Neurovance, Inc. Series A-1 (c)	3,581,463

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-Q

561,798	Ovid Therapeutics, Inc. Series B	3,500,002
		7,373,599
	TOTAL CONVERTIBLE PREFERRED AND WARRANTS	
	(Cost \$55,708,882)	44,851,503

The accompanying notes are an integral part of this Schedule of Investments.

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-Q

PRINCIPAL AMOUNT			VALUE
CONVERTIBLE AND NON-CONVERTIBLE NOTES		0.1% of Net Assets	
Convertible Notes (Restricted) (a) (c)		0.1%	
Health Care Equipment & Supplies		0.0%	
\$	414,000	Insightra Medical, Inc. Promissory Note, 8.00%, due 4/15/17	\$ 0
	43,658	Palyon Medical Corporation Promissory Note, 8.00%, due 7/15/16	0
			0
Pharmaceuticals		0.1%	
	134,622	Neurovance, Inc. Cvt. Promissory Note, 6.00%, due 3/1/17	134,622
	403,867	Neurovance, Inc. Cvt. Promissory Note, 6.00%, due 3/1/17	403,867
			538,489
TOTAL CONVERTIBLE NOTES			538,489
Non-Convertible Notes (Restricted) (a) (b)		0.0%	
Health Care Equipment & Supplies		0.0%	
	342,899	Tibion Corporation Non-Cvt. Promissory Note, 0.00%, due 12/31/18	0
	40,596	Tibion Corporation Non-Cvt. Promissory Note, 0.00%, due 12/31/18	0
TOTAL NON-CONVERTIBLE NOTES			0
TOTAL CONVERTIBLE AND NON-CONVERTIBLE NOTES			
		(Cost \$1,381,148)	538,489

SHARES

COMMON STOCKS AND WARRANTS		89.5% of Net Assets	
Biotechnology		54.2%	
175,299	ACADIA Pharmaceuticals Inc. (b)		5,690,206
348,916	Alexion Pharmaceuticals, Inc. (b)		40,739,432
278,717	Alkermes plc (b)		12,046,149
170,970	Alnylam Pharmaceuticals, Inc. (b)		9,487,125
122,083	Amgen Inc.		18,574,928
361,440	ARIAD Pharmaceuticals, Inc. (b)		2,671,042
187,390	Biogen Inc. (b)		45,314,650
406,545	BioMarin Pharmaceutical Inc. (b)		31,629,201
686,854	Celgene Corporation (b)		67,744,410
529,264	CytomX Therapeutics, Inc. (b)		5,406,432
733	Eiger BioPharmaceuticals, Inc. warrants (Restricted, expiration 10/10/18) (a) (b)		0
200,000	Epizyme, Inc. (b)		2,048,000
984,821	Exelixis, Inc. (b)		7,691,452
14,000	Galapagos NV (b) (d)		776,580
997,392	Gilead Sciences, Inc.		83,202,441
407,579	Heron Therapeutics, Inc. (b)		7,356,801
508,323	Incyte Corporation (b)		40,655,674
107,827	Medivation, Inc. (b)		6,501,968
130,000	Merus B.V. (b)		1,056,250

The accompanying notes are an integral part of this Schedule of Investments.

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-Q

SHARES		VALUE
	Biotechnology continued	
206,567	Merus B.V. (Restricted) (a) (b)	\$ 1,510,521
391,312	Natera, Inc. (b)	4,721,179
346,103	Neurocrine Biosciences, Inc. (b)	15,730,381
1,770,168	Pieris Pharmaceuticals, Inc. (b)	2,849,970
136,973	Pieris Pharmaceuticals, Inc. (Restricted) (a) (b)	198,474
54,790	Pieris Pharmaceuticals, Inc., Series A warrants (Restricted, expiration 6/8/21) (a) (b)	31,230
27,394	Pieris Pharmaceuticals, Inc., Series B warrants (Restricted, expiration 6/8/21) (a) (b)	18,902
109,644	Regeneron Pharmaceuticals, Inc. (b)	38,290,974
61,880	Ultragenyx Pharmaceutical Inc. (b)	3,026,551
474,879	Vertex Pharmaceuticals Incorporated (b)	40,849,092
		495,820,015
	Health Care Equipment & Supplies 2.6%	
240,300	Abbott Laboratories	9,446,193
1,155,000	Alliqua BioMedical, Inc. (b)	1,293,600
160,000	Cercacor Laboratories, Inc. (Restricted) (a) (b)	234,746
77,194	IDEXX Laboratories, Inc. (b)	7,168,235
60,590	Medtronic plc	5,257,394
10,735	TherOx, Inc. (Restricted) (a) (b)	215
		23,400,383
	Health Care Providers & Services 4.6%	
120,880	AmerisourceBergen Corporation	9,588,202
120,000	Centene Corporation (b)	8,564,400
91,826	HCA Holdings, Inc. (b)	7,071,520
222,222	InnovaCare Health, Inc. (Restricted) (a) (b) (g)	190,000
212,541	Molina Healthcare, Inc. (b)	10,605,796
48,076	Universal Health Services, Inc.	6,446,992
		42,466,910
	Life Sciences Tools & Services 6.2%	
227,150	Agilent Technologies, Inc.	10,076,374
240,532	Illumina, Inc. (b)	33,765,882
102,000	PRA Health Sciences, Inc. (b)	4,259,520
60,645	Thermo Fisher Scientific Inc.	8,960,905
		57,062,681
	Pharmaceuticals 21.9%	
91,893	Akorn, Inc. (b)	2,617,572
171,201	Allergan plc (b)	39,562,839
583,984	Auris Medical Holding AG (b)	2,446,893
85,667	Eli Lilly & Company	6,746,276
147,000	Endo International plc (b)	2,291,730
113,487	Flex Pharma, Inc. (b)	1,158,702
289,660	Foamix Pharmaceuticals Ltd. (b)	1,839,341
587,000	Horizon Pharma plc (b)	9,667,890
88,386	Impax Laboratories, Inc. (b)	2,547,285
131,460	Intra-Cellular Therapies, Inc. (b)	5,103,277
116,759	Jazz Pharmaceuticals plc (b)	16,499,214
382,868	The Medicines Company (b)	12,875,851
419,300	Mylan NV (b)	18,130,532

The accompanying notes are an integral part of this Schedule of Investments.

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-Q

SHARES		VALUE
Pharmaceuticals continued		
483,700	Paratek Pharmaceuticals, Inc. (b)	\$ 6,728,267
673,204	Pfizer, Inc.	23,703,513
286,650	Sagent Pharmaceuticals, Inc. (b)	4,294,017
119,885	Shire plc (f)	22,068,431
103,558	Tetraphase Pharmaceuticals Inc. (b)	445,299
430,658	Teva Pharmaceutical Industries Ltd. (f)	21,631,951
		200,358,880
TOTAL COMMON STOCKS AND WARRANTS (Cost \$618,598,764)		819,108,869
EXCHANGE TRADED FUND 1.6% of Net Assets		
57,670	iShares Nasdaq Biotechnology ETF	14,840,798
TOTAL EXCHANGE TRADED FUND (Cost \$11,259,769)		14,840,798
PRINCIPAL AMOUNT		
SHORT-TERM INVESTMENT 3.3% of Net Assets		
\$ 30,537,000	Repurchase Agreement, Fixed Income Clearing Corp., repurchase value \$30,537,000, 0.03%, dated 06/30/16, due 07/01/16 (collateralized by U.S. Treasury Bond 3.125%, due 02/15/43, market value \$31,148,997)	30,537,000
TOTAL SHORT-TERM INVESTMENT (Cost \$30,537,000)		30,537,000
TOTAL INVESTMENTS BEFORE MILESTONE INTEREST - 99.4% (Cost \$717,485,563)		909,876,659
INTEREST		
MILESTONE INTEREST (Restricted)(a) (b) 0.0% of Net Assets		
Pharmaceuticals 0.0%		
1	Targegen Milestone Interest	0
TOTAL MILESTONE INTEREST (Cost \$4,194,994)		0
TOTAL INVESTMENTS - 99.4% (Cost \$721,680,557)		909,876,659
OTHER ASSETS IN EXCESS OF LIABILITIES - 0.6%		5,834,546
NET ASSETS - 100%		\$ 915,711,205

- (a) Security fair valued. See Investment Valuation and Fair Value Measurements.
(b) Non-income producing security.
(c) Affiliated issuers in which the Fund holds 5% or more of the voting securities (total market value of \$18,907,450).
(d) Foreign security.
(e) Number of warrants to be determined at a future date.

The accompanying notes are an integral part of this Schedule of Investments.

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-Q

- (f) American Depositary Receipt
- (g) Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers.

The accompanying notes are an integral part of this Schedule of Investments.

TEKLA HEALTHCARE INVESTORS

NOTES TO SCHEDULE OF INVESTMENTS

JUNE 30, 2016

(Unaudited)

Investment Valuation

Shares of publicly traded companies listed on national securities exchanges or trading in the over-the-counter market are typically valued at the last sale price, as of the close of trading, generally 4 p.m., Eastern time. The Board of Trustees of the Fund (the Trustees) has established and approved fair valuation policies and procedures with respect to securities for which quoted prices may not be available or which do not reflect fair value. Convertible bonds, corporate and government bonds are valued using a third-party pricing system. Convertible bonds are valued using this pricing system only on days when there is no sale reported. Restricted securities of companies that are publicly traded are typically valued based on the closing market quote on the valuation date adjusted for the impact of the restriction as determined in good faith by the Adviser also using fair valuation policies and procedures approved by the Trustees described below. Non-exchange traded warrants of publicly traded companies are generally valued using the Black-Scholes model, which incorporates both observable and unobservable inputs. Short-term investments with a maturity of 60 days or less are generally valued at amortized cost, which approximates fair value.

Convertible preferred shares, warrants or convertible note interests in private companies, milestone interests, and other restricted securities, as well as shares of publicly traded companies for which market quotations are not readily available, such as stocks for which trading has been halted or for which there are no current day sales, or which do not reflect fair value, are typically valued in good faith, based upon the recommendations made by the Adviser pursuant to fair valuation policies and procedures approved by the Trustees.

The Adviser has a Valuation Sub-Committee comprised of senior management which reports to the Valuation Committee of the Board at least quarterly. Each fair value determination is based on a consideration of relevant factors, including both observable and unobservable inputs. Observable and unobservable inputs the Adviser considers may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, the company's products or intended markets or the company's technologies; (iii) the price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value. Significant unobservable inputs identified by the Adviser are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Due to the uncertainty inherent in the valuation process, such estimates of fair value may differ significantly from the values that would have been used had a ready market for the investments existed, and differences could be material. Additionally, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these financial statements.

Federal Income Tax Cost

At June 30, 2016, the cost of securities for Federal income tax purposes was \$721,681,200. The net unrealized gain on securities held by the Fund was \$188,195,459, including gross unrealized gain of \$271,469,134 and gross unrealized

loss of \$83,273,675.

Other Transactions with Affiliates

An affiliate company is a company in which the Fund holds 5% or more of the voting securities. Transactions involving such companies during the period ended June 30, 2016 were as follows:

Issuer	Value on September 30, 2015	Purchases	Sales	Income	Value on June 30, 2016
CardioKinetix, Inc.	\$ 6,169,346				\$ 18,854*
EBI Life Sciences, Inc.	18,854				4,119
Euthymics Biosciences, Inc.	1,582,914				1,846,848
IlluminOss Medical, Inc.	3,593,974	\$ 1,050,000	\$ 99,000		20,071
Insightra Medical, Inc.	8,496,358	414,000		\$ 6,992	4,407,967
Neurovance, Inc.	5,705,132	538,489		10,049	4,841
Palyon Medical Corporation	4,992		107,385	(8,909)	12,604,750
Veniti, Inc.	4,302,680				18,907,450
	\$ 29,874,250	\$ 2,002,489	\$ 206,385	\$ 8,132	\$ 18,907,450

* No longer an affiliate as of June 30, 2016.

TEKLA HEALTHCARE INVESTORS**NOTES TO SCHEDULE OF INVESTMENTS**

JUNE 30, 2016

(Unaudited)

(continued)

Fair Value Measurements

The Fund uses a three-tier hierarchy to prioritize the assumptions, referred to as inputs, used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels. Level 1 includes quoted prices in active markets for identical investments. Level 2 includes prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, etc.). The independent pricing vendor may value bank loans and debt securities at an evaluated bid price by employing methodologies that utilize actual market transactions, broker supplied valuations, and/or other methodologies designed to identify the market value for such securities and such securities are considered Level 2 in the fair value hierarchy. Level 3 includes prices determined using significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). These inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used as of June 30, 2016 to value the Fund's net assets. For the period ended June 30, 2016, there were no transfers between Levels 1 and 2. The Fund accounts for transfers between levels at the beginning of the period.

Assets at Value	Level 1	Level 2	Level 3	Total
Convertible Preferred and Warrants				
Biotechnology			\$ 11,319,197	\$ 11,319,197
Health Care Equipment & Supplies			20,160,879	20,160,879
Life Sciences Tools & Services			5,997,828	5,997,828
Pharmaceuticals			7,373,599	7,373,599
Convertible and Non-Convertible Notes				
Health Care Equipment & Supplies			0	0
Pharmaceuticals			538,489	538,489
Common Stocks and Warrants				
Biotechnology	\$ 494,060,888		1,759,127	495,820,015
Health Care Equipment & Supplies	23,165,422		234,961	23,400,383
Health Care Providers & Services	42,276,910		190,000	42,466,910
Life Sciences Tools & Services	57,062,681			57,062,681
Pharmaceuticals	200,358,880			200,358,880
Exchange Traded Fund	14,840,798			14,840,798
Short-term Investment		\$ 30,537,000		30,537,000
Other Assets			279,312	279,312
Total	\$ 831,765,579	\$ 30,537,000	\$ 47,853,392	\$ 910,155,971

The following is a reconciliation of level 3 assets for which significant unobservable inputs were used to determine fair value.

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-Q

	Balance as of September 30, 2015	Net realized gain (loss) and change in unrealized appreciation (depreciation)	Cost of purchases and conversions	Proceeds from sales and conversions	Net transfers in (out of) Level 3	Balance as of June 30, 2016
Level 3 Assets						
Convertible Preferred and Warrants						
Biotechnology	\$ 6,129,122	\$ 3,364,818	\$ 4,418,402	\$ (2,593,145)		\$ 11,319,197
Health Care Equipment & Supplies	26,344,438	(4,272,869)	967,733	(2,878,423)		20,160,879
Life Sciences Tools & Services	4,303,950	1,693,878				5,997,828
Pharmaceuticals	10,788,048	(3,420,351)	5,902			7,373,599
Convertible and Non-Convertible Notes						
Health Care Equipment & Supplies						
	151	(414,151)	454,598	(40,598)		0
Pharmaceuticals		(1,820)	540,309			538,489
Common Stocks and Warrants						
Biotechnology	6,082,338	(4,551,334)	3,030,594	(2,802,471)		1,759,127
Health Care Equipment & Supplies	145,447	89,514				234,961
Health Care Providers & Services	471,110	(281,110)				190,000
Pharmaceuticals	32,214	(32,214)				
Other Assets	380,021		77,766	(178,474)		279,312
Total	\$ 54,676,839	\$ (7,825,639)	\$ 9,495,304	\$ (8,493,111)	\$ 0	\$ 47,853,392
Net change in unrealized appreciation (depreciation) from investments still held as of June 30, 2016						\$ (4,557,536)

TEKLA HEALTHCARE INVESTORS**NOTES TO SCHEDULE OF INVESTMENTS**

JUNE 30, 2016

(Unaudited)

(continued)

The following is a quantitative disclosure about significant unobservable inputs used in the determination of the fair value of Level 3 assets.

	Fair Value at 6/30/2016	Valuation Technique	Unobservable Input	Range (Weighted Average)
Private Companies and Other Restricted Securities	\$ 284,878	Income approach Black-Scholes	Discount for lack of marketability	20% (20%)
	13,737,899	Adjusted capital asset pricing model	Discount rate Price to sales multiple	20.15%-39.34% (23.37%) 1.58-4.85 (2.32)
	33,551,303	Market approach, recent transaction	(a)	N/A
	279,312	Probability adjusted value	Probability of events Timing of events	10%-75% (33.92%) 0.25-2.58 (1.04) years
	\$ 47,853,392			

(a) The valuation technique used as a basis to approximate fair value of these investments is based upon subsequent financing rounds. There is no quantitative information to provide as these methods of measure are investment specific.

Private Companies and Other Restricted Securities

The Fund may invest in private companies and other restricted securities if these securities would currently comprise 40% or less of net assets. The value of these securities represented 5% of the Fund's net assets at June 30, 2016.

The following table details the acquisition date, cost, carrying value per unit, and value of the Fund's private companies and other restricted securities at June 30, 2016. The Fund on its own does not have the right to demand that such securities be registered.

TEKLA HEALTHCARE INVESTORS**NOTES TO SCHEDULE OF INVESTMENTS**

JUNE 30, 2016

(Unaudited)

(continued)

Security (#)	Acquisition Date	Cost	Carrying Value per Unit	Value
Afferent Pharmaceuticals, Inc.				
Series C Cvt. Pfd	7/1/15	\$ 3,503,978	\$ 4.83	\$ 6,890,728
AlterG, Inc.				
Series C Cvt. Pfd	4/12/13	2,053,934	0.41	1,379,536
BioClin Therapeutics, Inc.				
Series A Cvt. Pfd	1/19/16	1,009,704	0.65	1,009,616
CardioKinetix, Inc.				
Series C Cvt. Pfd	5/22/08	2,379,165	0.00	114
Series D Cvt. Pfd	12/10/10	785,619	2.55	522,765
Series E Cvt. Pfd	9/14/11	1,803,981	2.85	1,799,905
Series F Cvt. Pfd	12/04/14	1,982,283	3.42	1,982,049
Warrants (expiration 12/11/19)	12/10/09, 2/11/10	177	0.00	0
Warrants (expiration 6/03/20)	6/03/10, 9/01/10	177	0.00	0
Warrants (expiration 8/15/24)	8/15/14	181	0.00	0
Cercacor Laboratories, Inc. Common	3/31/98	0	1.47	234,746
Dynex Technologies, Inc.				
Series A Cvt. Pfd	1/03/12	287,751	0.50	1,554,931
Warrants (expiration 4/01/19)	1/03/12	86	0.00	0
Warrants (expiration 5/06/19)	1/03/12	7	0.00	0
EBI Life Sciences, Inc.				
Series A Cvt. Pfd	12/29/11	19,566	0.01	18,854
Eiger BioPharmaceuticals, Inc.				
Warrants (expiration 10/10/18)	10/10/13	359	0.00	0
Euthymics Biosciences, Inc.				
Series A Cvt. Pfd	7/14/10 - 5/21/12	3,792,631	0.00	4,119
GenomeDx Biosciences, Inc.				
Series C Cvt. Pfd	2/22/16	3,400,703	1.50	3,399,999
IlluminOss Medical, Inc.				
Series AA Cvt. Pfd	1/21/16	955,555	1.00	951,000
Series Junior Preferred Cvt. Pfd	9/26/12, 6/13/14, 1/21/16	3,461,754	1.00	895,848
InnovaCare Health, Inc. Common	12/21/12	965,291	0.86	190,000
Insightra Medical, Inc.				
Series C Cvt. Pfd	4/29/13 - 4/17/14	4,839,765	0.00	11,410
Series C-2 Cvt. Pfd	5/25/15	3,666,720	0.00	8,661
Cvt. Promissory Note	4/15/16	414,000	0.00	0
Warrants (expiration 3/31/25)	7/24/15	16	0.00	0
Warrants (expiration 5/28/25)	5/28/15	86	0.00	0
Warrants (expiration 8/18/25)	8/8/15	63	0.00	0
Labcyte, Inc.				
Series C Cvt. Pfd	7/18/05	1,925,938	1.17	4,274,413
Series D Cvt. Pfd	12/21/12	102,912	1.05	168,484
Merus B.V. Common	8/17/15	2,753,145	7.31	1,510,521
Neurovance, Inc.				

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-Q

Series A Cvt. Pfd	12/29/11	293,838	3.71	288,015
	10/11/12 - 10/10/13,			
Series A-1 Cvt. Pfd	3/17/15	3,594,700	3.71	3,581,463
Cvt. Promissory Note	2/23/16	135,077	100.00	134,622
Cvt. Promissory Note	3/14/16	405,232	100.00	403,867
Ovid Therapeutics, Inc.				
Series B Cvt. Pfd	8/7/15	3,500,002	6.23	3,500,002
Palyon Medical Corporation				
Series A Cvt. Pfd	4/28/09	2,978,923	0.00	2,944
Series B Cvt. Pfd	6/28/13	1,891,949	0.00	1,897
Cvt. Promissory Note	1/22/15	43,658	0.00	0
Warrants (expiration 4/26/19)	4/25/12	0	0.00	0
Pieris Pharmaceuticals, Inc.				
Common	6/7/16	265,728	1.45	198,474
Series A, Warrants (expiration 6/8/21)	6/7/16	6,849	0.57	31,230
Series B, Warrants (expiration 6/8/21)	6/7/16	3,424	0.69	18,902
Targeen Milestone Interest	7/20/10	4,194,994	0.00	0
TherOx, Inc. Common	9/11/00, 7/8/05	3,582,706	0.02	215
Tibion Corporation				
Series B Cvt. Pfd	2/23/11	1,302,544	0.00	0
Non-Cvt. Promissory Note	7/12/12	343,226	0.00	0
Non-Cvt. Promissory Note	4/12/13	40,598	0.00	0
Warrants (expiration 07/12/17)	7/12/12	0	0.00	0
Warrants (expiration 10/30/17)	10/30/12	0	0.00	0
Warrants (expiration 11/28/17)	11/28/12	0	0.00	0
Veniti, Inc.				
Series A Cvt. Pfd	2/28/11	3,270,355	1.83	6,880,013
Series B Cvt. Pfd	5/24/13	1,723,585	1.88	3,545,023
Series C Cvt. Pfd	12/12/14	1,180,235	2.11	2,179,714
		\$ 68,863,170		\$ 47,574,080

(#) See Schedule of Investments and corresponding footnotes for more information on each issuer.

Carrying value per unit is greater than \$0.00 but less than \$0.01

Interest received as part of a corporate action for a previously owned security.

Item 2. Controls and Procedures.

(a) The registrant's principal executive officer and principal financial officer have concluded, based on their evaluation of the registrant's disclosure controls and procedures as conducted within 90 days of the filing date of this report, that these disclosure controls and procedures are adequately designed and are operating effectively to ensure that information required to be disclosed by the registrant on Form N-Q is (i) accumulated and communicated to the investment company's management, including its certifying officers, to allow timely decisions regarding required disclosure; and (ii) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.

(b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the registrant's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 3. Exhibits.

Separate certifications for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)). Filed herewith.
